Non‐invasive assessment of liver fibrosis: reduce or substitute the need for liver biopsy?

A noninvasive model to predict liver histology in HBeAg‐positive chronic hepatitis B with alanine aminotransferase ≤ 2upper limit of normal

“…Previous studies already proposed several noninvasive models to predict liver histology in patients with CHB or chronic hepatitis C (CHC), 9,[11][12][13] which might reduce the clinical need for liver biopsy. [14][15][16] However, there is no model constructed to predict liver histology for commencing antiviral therapy in HBeAg-positive CHB patients with ALT ≤ 2ULN until now.…”

Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers

“…The clinical utilization of non‐invasive liver fibrosis assessment has been suggested to reduce but not substitute the need for liver biopsy. Dual cutoffs for ruling out and ruling in certain fibrosis stage should be determined for clinical application . VCTE generally performs better at ruling out (NPV higher than 90%) than ruling in (PPV lower than 90%) cirrhosis, which may be explained by the prevalence of cirrhosis far lower than 50% in studies results in the lower PPV.…”

Clinical Application of Vibration Controlled Transient Elastography in Patients with Chronic Hepatitis B

“…For the clinical application of LSM in staging fibrosis, it is rational to reduce the need of liver biopsy but not to substitute this gold standard. 10 A likelihood ratio, which is independent of disease prevalence, of >10 or <0.1 used in cutoff determination is strong enough to confirm or exclude a diagnosis. 11 Accordingly, only the residual patients with LSM falling within the so-called grey zone (i.e.…”